Moolec Science S.A.
MLEC · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -24.08 | 23.30 | -7.93 | 67.67 |
| FCF Yield | -0.03% | -0.02% | -0.02% | -0.04% |
| EV / EBITDA | -4,075.71 | -4,789.76 | -2,554.16 | -12,121.23 |
| Quality | ||||
| ROIC | -7.50% | -7.18% | -7.79% | -9.67% |
| Gross Margin | -25.52% | 0.95% | -4.70% | 4.35% |
| Cash Conversion Ratio | 0.37 | 0.59 | 0.41 | 1.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,985,879.02% | 1,758,855.45% | 1,778,359.83% | 1,710,681.76% |
| Free Cash Flow Growth | -0.29% | -10.70% | 59.88% | 34.07% |
| Safety | ||||
| Net Debt / EBITDA | -17.50 | -17.29 | -3.93 | -15.37 |
| Interest Coverage | -3.10 | -3.82 | -4.82 | -5.69 |
| Efficiency | ||||
| Inventory Turnover | 0.68 | 0.28 | 0.25 | 5.22 |
| Cash Conversion Cycle | 196.82 | 376.17 | 392.66 | 62.97 |